Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era.
Alpesh A AminFaris G ArajVenkatesh K AriyamuthuMark H DraznerMehmet U S AyvaciPradeep P A MammenMutlu MeteMarcus A UreyBekir TanrioverPublished in: Clinical transplantation (2019)
In this contemporary cohort of heart transplant recipients receiving TAC/MPA, neither r-ATG nor IL2-RA were associated with a survival benefit. On the contrary, adjusted analyses showed a significantly higher mortality in the r-ATG group and a trend toward higher mortality in the IL2-RA group. While caution is needed in interpreting treatment effects in an observational cohort, these data call into question the benefit of induction therapy as a common practice and highlight the need for more studies.
Keyphrases
- rheumatoid arthritis
- cardiovascular events
- heart failure
- disease activity
- primary care
- healthcare
- risk factors
- atrial fibrillation
- case report
- electronic health record
- ankylosing spondylitis
- stem cells
- type diabetes
- coronary artery disease
- big data
- systemic lupus erythematosus
- mesenchymal stem cells
- newly diagnosed
- artificial intelligence
- idiopathic pulmonary fibrosis
- smoking cessation